Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United States
26 Settembre 2023 - 12:59PM
Business Wire
First of its Kind Specialty Eye Care
Products Clinically Proven to Support Beautiful, Healthy-Looking
Eyes
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye
health company dedicated to helping people see better to live
better, today announced the U.S. launch of LUMIFY EYE
ILLUMINATIONS, a new line of hypoallergenic specialty eye care
products scientifically developed to cleanse, nourish and brighten
the sensitive eye area.
“Many products contain chemicals or preservatives that can
irritate the delicate area of and around the eye,” said John
Ferris, executive vice president, Consumer, Bausch + Lomb. “Free
from harsh, irritating ingredients, LUMIFY EYE ILLUMINATIONS were
developed with both ophthalmologists and dermatologists and are
clinically proven to deliver visibly beautiful results.”
Each product in the LUMIFY EYE ILLUMINATIONS line has been
formulated with clean, nutrient rich ingredients and contains no
fragrance, alcohol, sulfates, mineral oil, prostaglandins, PEG
(polyethylene glycol), parabens, phthalates or PHMB
(polyhexamethylene biguanide). In addition, the safety and
performance of the products were tested up to 12 weeks with more
than 15,000 applications using cutaneous and ophthalmic testing
metrics.
The LUMIFY EYE ILLUMINATIONS product line, which builds on the
success of LUMIFY® redness reliever eye drops, includes:
- LUMIFY EYE ILLUMINATIONS 3-in-1 Micellar Cleansing Water and
Eye Makeup Remover – this unique, lash extension friendly,
no-rinse micellar formula provides powerful cleansing while
hyaluronic acid, vitamin C and niacinamide moisturize and brighten
the delicate skin around the eyes. The solution removes waterproof
makeup without harsh rubbing and is pH-balanced to be
non-irritating.
- In clinical studies, subjects’ skin looked brighter, smoother
and more radiant within just two weeks. By week eight, more than
75% of respondents felt their skin looked healthier and rejuvenated
with an improved texture.
- LUMIFY EYE ILLUMINATIONS Nourishing Lash & Brow
Serum – a unique complex of peptides, biotin and moisturizing
hyaluronic acid nourish, soften and condition lashes and brows
overnight. In clinical studies, noticeably fuller looking lashes
and brows were seen in just four weeks. The two-in-one serum
includes an easy-to-use applicator for both lashes and brows and
dries quickly without feeling greasy or sticky.
- In clinical studies, nearly 80% of subjects showed an
improvement in the appearance of lash volume at 12 weeks, and 91%
showed an improvement in the appearance of brow thickness.
- LUMIFY EYE ILLUMINATIONS Hydra-Gel Brightening Eye Cream
– a unique blend of optic brighteners and firming ingredients helps
skin look brighter and smoother with a subtle glow. Niacinamide,
vitamins C and E, caffeine and hyaluronic acid help improve the
appearance of skin tone, texture, fine lines and wrinkles with
daily use.
- By week 12 in clinical studies, approximately 70% of
respondents noticed a reduction in the appearance of fine lines and
wrinkles.
“An increasing number of my patients have experienced eye
irritation associated with some of the products or treatments they
use around their eyes,” said Jennifer Tsai, O.D., and founder, LINE
OF SIGHT, New York. “LUMIFY EYE ILLUMINATIONS was developed
specifically for the sensitive eye area with extensive safety and
performance testing. I’ll be recommending this new line of products
to help my patients achieve beautiful, healthy-looking eyes.”
LUMIFY EYE ILLUMINATIONS are located in the eye care aisle next
to Bausch + Lomb LUMIFY redness reliever eye drops and are also
available online at all major national food, drug and mass
retailers.
For more information on LUMIFY EYE ILLUMINATIONS, visit
www.lumifyeyes.com.
About the LUMIFY Brand The LUMIFY brand began in 2018
with the U.S. introduction of LUMIFY redness reliever eye drops,
which are the first and only over-the-counter eye drop formulated
with low-dose brimonidine tartrate 0.025% for the treatment of
ocular redness. They are the No. 1 eye doctor recommended redness
reliever eye drop brand with approximately 90% of doctor
recommendations1, and they have received more than a dozen awards,
including Glamour's "The Best Beauty Innovators of 2022" award. In
2023, Bausch + Lomb introduced LUMIFY EYE ILLUMINATIONS, a new line
of specialty eye care products specifically developed for the
sensitive area around the eyes. For more information on the LUMIFY
brand, visit www.lumifyeyes.com.
About Bausch + Lomb Bausch + Lomb is dedicated to
protecting and enhancing the gift of sight for millions of people
around the world – from the moment of birth through every phase of
life. Its comprehensive portfolio of more than 400 products
includes contact lenses, lens care products, eye care products,
ophthalmic pharmaceuticals, over-the-counter products and
ophthalmic surgical devices and instruments. Founded in 1853,
Bausch + Lomb has a significant global research and development,
manufacturing and commercial footprint with approximately 13,000
employees and a presence in nearly 100 countries. Bausch + Lomb is
headquartered in Vaughan, Ontario with corporate offices in
Bridgewater, New Jersey. For more information, visit www.bausch.com
and connect with us on Twitter, LinkedIn, Facebook and
Instagram.
Forward-looking Statements This news release may contain
forward-looking statements, which may generally be identified by
the use of the words “anticipates,” “hopes,” “expects,” “intends,”
“plans,” “should,” “could,” “would,” “may,” “believes,”
“estimates,” “potential,” “target,” or “continue” and variations or
similar expressions. These statements are based upon the current
expectations and beliefs of management and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to, the
risks and uncertainties discussed in Bausch + Lomb’s filings with
the U.S. Securities and Exchange Commission and the Canadian
Securities Administrators, which factors are incorporated herein by
reference. Readers are cautioned not to place undue reliance on any
of these forward-looking statements. These forward-looking
statements speak only as of the date hereof. Bausch + Lomb
undertakes no obligation to update any of these forward-looking
statements to reflect events or circumstances after the date of
this news release or to reflect actual outcomes, unless required by
law.
*at eight weeks
References
- IQVIA, Average Share of Weekly Doctor Recommendations, Q2
2023.
© 2023 Bausch + Lomb. LUM.0061.USA.23
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230926043168/en/
Media: Lainie Keller lainie.keller@bausch.com (908)
927-1198
Kristy Marks kristy.marks@bausch.com (908) 927-0683
Investor: George Gadkowski george.gadkowski@bausch.com
(877) 354-3705 (toll free) (908) 927-0735
Grafico Azioni Bausch plus Lomb (NYSE:BLCO)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Bausch plus Lomb (NYSE:BLCO)
Storico
Da Set 2023 a Set 2024